TB-500 dosage in the research literature — what was administered, to which species, by which route.

TB-500 Dosage in the Research Literature

TB-500 dosage in the research literature is best read as a record of study parameters, not a protocol. Animal studies dosed full-length thymosin beta-4 across a wide range: roughly 6 to 12 mg/kg in cardiac and neurological rodent models, and 2 to 18 mg/kg intraperitoneally in the embolic-stroke dose-response study (modeled optimal near 3.75 mg/kg) ^[9]. A muscular-dystrophy study used 150 µg twice weekly intraperitoneally for six months ^[1].

The non-monotonic result is the one worth holding onto. In that stroke dose-response work, 2 and 12 mg/kg improved outcomes but 18 mg/kg did not ^[9]. Higher was not better — which directly undercuts the community "loading" rationales that have no basis in controlled human trials ^[1].

In humans, the only controlled dosing belongs to the full-length protein: intravenous synthetic thymosin beta-4 at 42, 140, 420, and 1260 mg (single dose, then daily for 14 days), well tolerated to the top dose ^[5]. Picogram-to-nanogram amounts are bioactive in vitro — around 10 pg is active in keratinocyte migration assays ^[3]. None of these are human recommendations for the seven-mer, and this digest does not convert them into one.

Routes, stability, and the absence of a human protocol

The routes studied are specific. Intraperitoneal administration predominates in rodent efficacy work; intravenous appears in the human Phase 1 of full-length thymosin beta-4 ^[5] and some cardiac models; topical and ophthalmic routes carry the corneal and dermal wound and dry-eye work (full-length protein / RGN-259) ^[12]. Subcutaneous and intramuscular routes circulate in research-use communities but are not drawn from controlled human efficacy trials ^[1].

Material handling is mundane but relevant. TB-500 is supplied as a lyophilized powder for research use, reconstituted in bacteriostatic or sterile water and kept refrigerated. As a short acetylated peptide it is more robust than the full-length protein, yet still subject to proteolysis and freeze-thaw degradation, and the identity and purity of research-grade material is a recurring concern ^[1].

Non-clinical "loading then maintenance" schedules that appear in athletic and peptide-research forums are not derived from controlled human trials and have no published clinical validation. This page does not reproduce them as dosing.

TB-500 Half-Life and Pharmacokinetics

TB-500 half-life is, for the fragment, an open figure. No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide ^[1]. The closest data point is parent-protein: in the intravenous full-length thymosin beta-4 Phase 1 study, half-life increased with dose, and overall pharmacokinetics were dose-proportional ^[5].

The anti-doping literature characterizes TB-500 and its metabolites in equine plasma and urine for detection purposes — to find it, not to model human PK ^[1]. So the available pharmacokinetic picture is either parent-protein human data or fragment detection data, with no validated human half-life for the seven-mer itself.

TB-500 Half-Life and Pharmacokinetics

No validated human pharmacokinetic half-life exists for the TB-500 heptapeptide ^[1]. In the intravenous full-length thymosin beta-4 Phase 1 study, half-life increased with dose and PK was dose-proportional ^[5]. Anti-doping LC-MS work characterizes TB-500 and its metabolites in equine matrices for detection, not for human pharmacokinetics ^[1].

Reading dose figures across species and scale

Dose figures only mean something attached to their species, route, and scale, and the TB-500 record spans an enormous range when you line them up. In rodents, efficacy work clusters in the milligrams-per-kilogram band — roughly 2 to 18 mg/kg intraperitoneally in the stroke dose-response study ^[9], 6 to 12 mg/kg in cardiac and neurological models, and a fixed 150 µg twice-weekly schedule over six months in the muscular-dystrophy work ^[1]. In humans, the only controlled exposure was fixed total doses of full-length thymosin beta-4 — 42, 140, 420, and 1260 mg intravenously — not weight-normalized ^[5].

The in-vitro end of the scale is smaller by orders of magnitude: around 10 pg of thymosin beta-4 was active in keratinocyte migration assays ^[3]. None of these convert into a human research-use figure for the seven-mer, and the gap between an in-vitro picogram and a rodent milligram-per-kilogram dose is exactly why cross-context extrapolation is unreliable.

Two cautions close the dose picture. The non-monotonic stroke result — 18 mg/kg underperforming 12 mg/kg ^[9] — means a dose-response curve for this biology can bend downward, so "more" is not a safe assumption. And because research-grade material varies in identity and purity ^[1], a stated reconstitution concentration is only as meaningful as the verified content of the vial, which is the due-diligence point this site keeps returning to.